Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV2-2303 secondary HPV vaccination after treatment of high-grade cervical lesions
2024-513081-19-00Phase 2Authorised
- Sponsor
- Centre Oscar Lambret
- Start
- Oct 2024
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of recombinant human papillomavirus 9-valent vaccine in cervical intraepithelial neoplasia (CIN) (2 cohorts), sponsored by Centre Oscar Lambret. Planned start Oct 2024; status: authorised.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on 2024-513081-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513081-19-00.